Prellis Biologics and start-up Volumetric Bio plan to commercialise their bioprinting projects. San Francisco-based Prellis, which raised $8.7m in funding in July, aims to market its 3D-printed vascular scaffolds, as well as vascularised skin grafts and a vascular shunt for dialysis patients made from their own tissue. The company is also working on the development of biodegradable tissue that can be used by surgeons or other medical professionals without damaging it.
Prellis Biologics and start-up Volumetric Bio plan to commercialise their bioprinting projects. San Francisco-based Prellis, which raised $8.7m in funding in July, aims to market its 3D-printed vascular scaffolds, as well as vascularised skin grafts and a vascular shunt for dialysis patients made from their own tissue. Meanwhile, Volumetric was launched to commercialise the bioprinters, materials and reagents supporting research into vascular networks.